Recorded live at AI in GxP West
How Large Enterprises Pilot AI in GxP
From idea to proof of concept: how a global pharmaceutical organization frames, tests, and governs an AI pilot inside a regulated environment, and what it takes to move one past the proof stage.
Stephen J. Cook
Senior Director, GRC CSO and Tech Operations, Global Digital & Tech, GSK
What you'll take away
- Choosing a first use case with a real owner and a measurable outcome
- The evidence a quality organization needs before a pilot is taken seriously
- The risk and accountability questions that decide whether a pilot ever scales
- Where enterprise pilots stall across IT, quality, and the business, and what separates the ones that don't
Complimentary access
Watch the full session
The full recording opens immediately. No membership, no charge.
By requesting access you agree to receive communications from KENX. Unsubscribe anytime.
Full session
On demand
No cost
Access granted
How Large Enterprises Pilot AI in GxP
Sessions like this one are what AI in GxP East is built on. Keep scrolling for 35+ more, live in Raleigh on September 15 and 16.
If you liked this session, there are 35+ more like it at
AI in GxP Canada
Early Bird rates end August 28 · From $1,795 · Register 3, the 4th is free
September 22 and 23, 2026 · Toronto, ON, Canada
Where the rest of the sessions are.
Two days of case studies, panels, and deep dives from the people actually deploying AI in validated environments — covering regulatory alignment, deviation intelligence, continuous validation, cleanroom vision systems, and the inspection questions nobody has clean answers to yet.
Featured session · Day One
From Idea to Proof of Concept: How Enterprises Pilot AI in GxP
Bryan Ennis, Founder & Chief Quality Officer, SWARE
An all-industry panel on how AI initiatives are actually framed, tested, and governed inside regulated environments — with panelists from Altis Labs.
Also on the agenda
Deviation Intelligence: Accelerating Investigations Without Sacrificing Compliance
Chip Bennett, Senior Director, ProjectFarma
How AI-enabled workflows are improving root cause analysis, cutting investigation cycle time, and supporting right-first-time deviation closure.
“A must-attend event for me in 2026, confirmed through the quality of the speakers and breadth of content. It answered key questions and sparked a wealth of ideas.”
AI IN GXP WEST ATTENDEE
Speaking from inside the regulated world
Who is on the faculty.
Case studies from the quality, validation, and IT leaders accountable when AI touches a GxP system.
NOVATEK
ProPharma
Pharmalytik LLC
The Hospital for Sick Children
Pfizer
Afiniti
Phanero
GSK
Allucent
Altis Labs
Genari AI
VTI Life Sciences
Avidity Biosciences, Inc.
SWARE
ProjectFarma
TADA Pharma Consulting
See 35 more sessions like this one.
Canada, September 22 and 23. Early Bird Pricing end August 28.
Manufacturer $1,795, rising to $1,995 after August 28 · Solution provider $1,995, rising to $2,195.
